Metacrine Reports Fourth-Quarter 2021 Results

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated...

Related Keywords

Preston Klassen ,Exchange Commission ,Drug Administration ,Metacrine Inc ,Nasdaq ,Private Securities Litigation Reform Act ,Annual Report ,Preferred Stock ,Nasdaq Mtcr ,Metacrine ,Nc ,Bd ,Inflammatory Bowel Disease ,Ulcerative Colitis ,